A Multiple Dose Study of the Safety, Tolerability and PK of CMX157 in Healthy Subjects

NCT02585440 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Infectious Disease

Interventions

DRUG: CMX157
DRUG: placebo

Sponsor

ContraVir Pharmaceuticals, Inc.